Tech Company Financing Transactions
Imago BioSciences Funding Round
On 11/20/2020, Imago BioSciences raised $80 million in Series C financing from Farallon Capital Management, Amgen Ventures and BlackRock.
Transaction Overview
Company Name
Announced On
11/20/2020
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
Proceeds Purpose
Imago will use the proceeds to complete a Phase 3 study of bomedemstat for the treatment of myeloproliferative neoplasms.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
We are a company dedicated to translating state-of-the art science into novel medicines for the treatment of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hugh Rienhoff
Chief Operating Officer
Laura Eichorn
Vice President
Jennifer Peppe
Vice President
Amy Tapper
VP - Bus. Development
Ed Baracchini
Browse more venture capital transactions:
Prev: 11/20/2020: Cardless venture capital transaction
Next: 11/20/2020: Stride Health venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs